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Complement activation is of major importance in numerous pathological conditions. Therefore, 
targeted complement inhibition is a promising therapeutic strategy. C1-esterase inhibitor (C1-INH) 
controls activation of the classical pathway (CP) and the lectin pathway (LP). However, conflicting 
data exist on inhibition of the alternative pathway (AP) by C1-INH. The inhibitory capacity of C1-
INH for the CP is potentiated by heparin and other glycosaminoglycans, but no data exist for the LP 
and AP. The current study investigates the effects of C1-INH in the presence or absence of different 
clinically used heparinoids on the CP, LP, and AP. Furthermore, the combined effects of heparinoids 
and C1-INH on coagulation were investigated. C1-INH, heparinoids or combinations were analyzed 
in a dose-dependent fashion in the presence of pooled serum. Functional complement activities were 
measured simultaneously using the Wielisa(®) -kit. The activated partial thrombin time was determined 
using an automated coagulation analyzer. The results showed that all three complement pathways were 
inhibited significantly by C1-INH or heparinoids. Next to their individual effects on complement 
activation, heparinoids also enhanced the inhibitory capacity of C1-INH significantly on the CP and LP. 
For the AP, significant potentiation of C1-INH by heparinoids was found; however, this was restricted 
to certain concentration ranges. At low concentrations the effect on blood coagulation by combining 
heparinoids with C1-INH was minimal. In conclusion, our study shows significant potentiating effects 
of heparinoids on the inhibition of all complement pathways by C1-INH. Therefore, their combined 
use is a promising and a potentially cost-effective treatment option for complement-mediated diseases.
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Introduction
The complement system is a major component of innate immunity. Excessive activation or insufficient 
regulation of the complement cascade causes clinical manifestations of many diseases such as 
paroxysmal nocturnal hemoglobinuria1, atypical hemolytic uremic syndrome2 or ischemia-reperfusion 
injury in transplantation.3–7 Therefore, inhibition of complement activation has been recognized as a 
promising therapeutic strategy. 
 In renal disease, terminal complement inhibitors such as eculizumab are approved for the 
treatment of atypical hemolytic uremic syndrome.1,2 In transplantation, mounting evidence from 
animal studies suggests that intervention in complement pathway activation is a promising method for 
improving allograft outcome.8,9 
Human C1-inhibitor (C1-INH) is a naturally occurring serine protease inhibitor that inhibits 
activation of the Classical pathway (CP) and the Lectin pathway (LP). However, conflicting data exist 
on inhibition of the Alternative pathway (AP) by C1-INH.10–12 In the CP, activation of the C1-complex 
results in cleavage of respectively C4 and C2, leading to the formation of the C4b2b convertase thereby 
activating C3. CP activation is tightly regulated by C1-INH through binding of activated C1r and C1s 
and subsequent dissociation from C1q. The LP is activated when mannose-binding lectin (MBL) and/or 
Ficolins, interact with carbohydrate moieties on microbes and altered self-surfaces. Activation of MBL-
associated serine proteases 1 (MASP-1) and MBL-associated serine proteases 2 (MASP-2) results in 
cleavage of C4, C2, and formation of the C4b2b-complex, thereby activating C3. MASPs are also 
inhibited by C1-INH thereby interfering in the LP activation.13,14 Recently, it was demonstrated that C1-
INH could also inhibit complement activation of the AP. Although the exact mechanism is not exactly 
clear, it is postulated that C1-INH binds C3b and inhibits the binding of factor B thereby blocking the 
AP convertase.12 
Besides regulation of complement activation, C1-INH is also involved in the contact system, 
coagulation, and fibrinolysis. C1-INH has been shown to inhibit activated Factor XII15,16, kallikrein17, 
thrombin18 platelets19 and plasmin.20 Treatment using C1-INH has been approved for hereditary 
angioedema.21,22 It is well known that glycosaminoglycans potentiate the inhibitory capacity of C1-
INH. Glycosaminoglycans are naturally occurring compounds in the human body, such as heparin. 
Heparin has been proposed to be one of the most potent enhancers of C1-INH function.23 In addition, 
heparin and related compounds possess anti-inflammatory effect.24,25 Low molecular weight heparins, 
also called heparinoids, are synthetic glycosaminoglycans with similar properties compared to heparin. 
At the moment, the potentiating effect of heparinoids via C1-INH has only been demonstrated for the 
CP. Moreover, the effects of clinical heparinoids on complement activation have not been investigated 
yet. Combined treatment with heparinoids and C1-INH are considered for clinical use, for example in 
the reduction of ischemia-reperfusion injury during transplantation or other diseases with excessive 
activation or inappropriate complement regulation. Therefore, the parallel and or combined effects of 
heparinoids on C1-INH via the LP and AP should be investigated. 
The aim of this study is to investigate the effects of purified plasma C1-INH in the presence 
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or absence of clinically employed heparinoids on the inhibition of the Classical, Lectin and Alternative 
pathway in vitro. 
Materials and Methods
Drugs
Heparin (5000 IU/ml) was purchased from Leo Pharma, Amsterdam, The Netherlands, dalteparin 
(Fragmin©, 10000 IU/ml) from Pfizer, New York, USA, enoxaparin (Clexane©, 10000 IU/ml) from 
Sanofi-Aventis, Paris, France, and nadroparin (Fraxiparin©, 9500 IU/ml) from GlaxoSmithKline, 
Brentford, UK. Plasma derived C1-inhibitor (CinryzeÒ) was a gift from Viropharma, Exton, USA. 
Blood samples
Blood samples were taken from 10 healthy volunteers and directly stored on ice to prevent in vitro 
complement activation. Serum samples were centrifuged, pooled and stored in aliquots at -80°C until 
further analysis. For plasma samples, blood was drawn into 3.2% sodium citrate, after which the plasma 
samples were pooled and stored in aliquots at −80 °C until use.
Complement pathway activity in human serum
The Wieslab Complement System Screen COMPL300 kit (Euro-Diagnostica AB, Malmö, Sweden) 
was used for the assessment of serum complement functional activity in classical, alternative, and 
Lectin pathways.26 In this kit, wells are pre-coated with IgM (CP), LPS (AP) and mannan (LP) to 
assess activity of each complement pathway specifically. Pooled human sera from healthy volunteers 
were diluted in specific buffers according to each complement pathway. For CP activity, serum was 
diluted 1:100 in Veronal buffer containing both free calcium and magnesium. For LP activity, serum 
was diluted 1:100 in Veronal buffer containing free calcium, magnesium, and monoclonal anti-C1q 
antibodies. For AP activity, serum was diluted in 1:18 in Mg-EGTA buffer containing free magnesium 
without calcium. Sera in pathway specific buffers were incubated in the presence or absence of C1-
INH (range 0 – 6 U/ml), heparin, dalteparin, enoxaparin and/or nadroparin (range 0 – 1 IU /ml). 
These mixtures were incubated for 1 hour at 37ºC. After 3 times washing, plates were incubated with 
phosphatase-conjugated anti-human C5b-9 (aE11) for 30 minutes at room temperature. After 3 times 
washing, plates were incubated with substrate solution for 30 minutes. After the reaction was stopped 
with 0.5 M H2SO4, the amount of reacted substrate was measured at OD 450 nm. Data are expressed 
as the percentage inhibition compared to the positive control (normal human serum) for each pathway. 
Blood coagulation time
The activated partial thrombin time (APTT) was determined in plasma samples using an automated 
coagulation analyzer (Behring Coagulation System, BCS) with reagents and protocols from the 
manufacturer (Siemens Healthcare Diagnostics, Marburg, Germany).
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Statistics 
Data are displayed as mean and ± SEM. Statistical analyses were performed using BM SPSS Statistics 
Version 22 and P values less than 0.05 were assigned statistically significant. Dose-response data 
of C1-INH and heparinoids alone were analyzed by linear regression. For linear regression, normal 
distribution of the residuals was tested and confirmed using normal probability plots. If needed, data 
were ln-transformed for normality. The area under the curve (AUC) was used to compare the combined 
effect of C1-INH and heparinoids with the individual effect. AUC was calculated using the Trapezoidal 
Rule and compared by Student’s t-test. 
Ethics 
The study was approved by the Regional Ethical Committee.
Results
Complement pathway activity in the presence of C1-INH (Figure 1).
To investigate the direct effect of C1-INH on the complement system, the activity of each pathway was 
studied. Analysis of the data by linear regression showed significant dose-dependent inhibition of the 
CP (P < 0.001), LP (P = 0.009) and AP (P < 0.001) by C1-INH. Complement activities of the CP, LP, 
and AP were reduced by 96%, 100% and 85% respectively, using 6 U/mL of C1-INH.
Figure 1
The dose-dependent inhibitory effect of C1-INH on the three complement pathways. 
Increasing concentrations of C1-INH were added to pooled human serum (x-axis, log
2
 scale). The inhibition of C5b-9 deposition 
was calculated by dividing the OD of the sample with added C1-INH by the control, which had no extra C1-INH (y-axis). Data are 
mean and S.E.M. of n = 3 experiments.
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Complement pathway activity in the presence of heparinoids (Figure 2).
Prior to the potentiating effect of heparinoids on C1-INH, the direct effects of heparinoids on 
complement were analyzed. Once again, analysis by linear regression showed that all three pathways 
were significantly inhibited by increasing concentrations of heparin (P < 0.01), dalteparin (P < 0.05), 
nadroparin (P < 0.05) and enoxaparin (P < 0.001). Interestingly, the different heparinoids vary in their 
ability to inhibit the different complement pathways. Heparin was the strongest inhibitor of the CP with 
54% inhibition at the lowest concentrations (0.0625 IU/ml). For the LP the most powerful inhibitor was 
dalteparin with 62% inhibition at the lowest concentrations (0.0625 IU/ml). However, for the AP the 
most potent inhibitor was strictly concentration-dependent. 
Figure 2
The inhibitory effect of heparin dalteparin, nadroparin and enoxaparin on the three complement pathways.
 
Increasing concentrations were added to pooled human serum samples (x-axis, log
2
 scale). The inhibition of C5b-9 deposition 
was calculated by dividing the OD of the sample with heparinoid by the control, the sample without heparinoid (y-axis). Data are 
expressed in the mean and S.E.M. of n = 3 experiments.
Complement pathway activity in the presence of C1-INH combined with heparinoids (Figure 3 - 6). 
Next, the combined effect of C1-INH and heparinoids on complement activity was evaluated. Different 
concentrations of heparinoids were incubated with increasing concentrations of C1-INH and vice versa 
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(supplementary data). The addition of heparinoids potentiated the inhibitory effect of C1-INH. To 
determine the concentration per heparinoid at which the maximal potentiation was reached, the AUC 
was compared. This was done separately for each heparinoid. The maximal potentiation was achieved 
at 0.5 IU/ml for heparin (Figure 3), 0.25 IU/ml for dalteparin (Figure 4), 0.0625 IU/ml for enoxaparin 
(Figure 5), 0.125 IU/ml for nadroparin (Figure 6). The AUC was significantly greater (P < 0.05) for 
the CP, LP, and AP when C1-INH was maximally potentiated with heparin, dalteparin, enoxaparin or 
nadroparin than C1-INH alone as shown in Figures 3 – 6 (A, C, E). This demonstrates that inhibition by 
C1-INH is significantly potentiated for all three pathways when combined with heparinoids. However, 
for the AP, potentiation was restricted to certain concentration ranges and in certain cases, the addition 
of higher concentrations of heparinoids to C1-INH lead to less potentiation or even loss of inhibition 
(supplementary data). 
Figure 3 Inhibition of C1-INH in combination with dalteparin on the classical pathway (A, B), lectin pathway (C, D) and the 
alternative pathway (E, F). 
Increasing concentrations of C1-INH were co-incubated with 0.25 IU/mL dalteparin (A, C and E) or increasing concentrations 
dalteparin were co-incubated with a 0.375 U/mL C1-INH (B, D, and F) in pooled human serum (x-axis, log
2
 scale). The inhibition 
of C5b-9 deposition was calculated by dividing the OD of the sample with heparinoid by the control, the sample without heparinoid 




Inhibition of C1-INH in combination with enoxaparin on the classical pathway (A, B), lectin pathway (C, D) and the alternative 
pathway (E, F). 
Increasing concentrations of C1-INH were co-incubated with 0.125 IU/mL enoxaparin (A, C and E) or increasing concentrations 
enoxaparin were co-incubated with 0.375 U/mL C1-INH (B, D, and F) in pooled human serum (x-axis, log
2
 scale). The inhibition 
of C5b-9 deposition was calculated by dividing the OD of the sample with heparinoid by the control, the sample without heparinoid 
(y-axis). Data are expressed in the mean and S.E.M. of n = 3 experiments.
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Figure 5
Inhibition of C1-INH in combination with heparin on the classical pathway (A, B), lectin pathway (C, D) and the alternative pathway 
(E, F).
 
Increasing concentrations of C1-INH were co-incubated with 0.5 IU/mL heparin (A, C, and E) or increasing concentrations heparin 
were co-incubated with 0.375 U/mL C1-INH (B, D, and F) in pooled human serum (x-axis, log
2
 scale). The inhibition of C5b-9 
deposition was calculated by dividing the OD of the sample with heparinoid by the control, the sample without heparinoid (y-axis). 




Inhibition of C1-INH in combination with nadroparin on the classical pathway (A, B), lectin pathway (C, D) and the alternative 
pathway (E, F). 
Increasing concentrations of C1-INH were co-incubated with 0.0625 nadroparin (A, C, and E) or increasing concentrations 
nadroparin were co-incubated with 0.375 U/mL C1-INH (B, D, and F) in pooled human serum (x-axis, log
2
 scale). The inhibition 
of C5b-9 deposition was calculated by dividing the OD of the sample with heparinoid by the control, the sample without heparinoid 
(y-axis). Data are expressed in the mean and S.E.M. of n = 3 experiments.
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Blood coagulation time in the presence of C1-INH, heparinoids or both (Figure 7 & 8)
The effects of C1-inhibitor alone and in combination with heparinoids on the blood coagulation times 
were analyzed. C1-INH and heparinoids both prolong the APTT in a dose-dependent manner (Figures 
7 & 8). The APTT was only found to be above the normal reference values (23 – 33 seconds) at the 
highest concentrations of C1-INH. The APTT was prolonged when C1-INH was co-incubated with 
heparinoids. However, at lower concentrations the combined effect of C1-INH and heparinoids on the 
APTT is minimal. Heparin combined with C1-INH prolonged the APTT the most. 
Figure 7
The effect of C1-INH on the APTT. 
Increasing concentrations of C1-INH were added to pooled human plasma samples (x-axis). The dashed line represents the upper 




The effect of C1-INH in combination with nadroparin, enoxaparin, dalteparin, and heparin on the APTT.
  
Increasing concentrations of C1-INH combined with heparinoids were added to pooled human plasma samples (x-axis). The dashed 
line represents the upper limit of normal (y-axis). Data are expressed in the mean and S.E.M. of n = 3 experiments.
 Discussion
Therapeutic inhibition of the complement system is considered a promising approach for the treatment 
of numerous pathological conditions.1,2,8,9 The current study demonstrates that C1-INH might be a 
potential therapeutic candidate because it inhibits activation of all three pathways of the complement 
system. Furthermore, treatment with C1-INH in combination with heparinoids could potentially 
significantly enhanced the inhibitory capacity of C1-INH considering the in vitro data of our study. For 
the CP and LP, the potentiating effect was minor due to the already profound effect of C1-INH alone. 
However, optimal potentiating effects of heparinoids on the CP and LP are found at low concentrations 
of C1-INH. There is a strong potentiating effect of heparinoids and C1-INH on the inhibition of the 
AP but this was found to be strictly dose-dependent. The effect on blood coagulation by the combined 
use of heparinoids and C1-INH is minimal as long as both agents are used at low concentrations. This 
study, therefore, shows a potentiating effect of heparinoids and C1-INH to inhibit all three complement 
pathways in vitro. The combined use of these agents is a promising and cost-effective therapeutic 
approach for clinical intervention in complement-mediated diseases. 
C1-INH is already approved for treatment of patients with hereditary angioedema.21,22 Our 
study demonstrates inhibition of all complement pathways by C1-INH which is supported by previous 
studies.10–12 Although most reports have focused on only one pathway, Nielsen et al. investigated the 
123
New insight in the effects of heparinoids on complement inhibition by C1-inhibitor.
7
effects of C1-INH on all three pathways using the same functional assay. In contrast to Nielsen et 
al, our study demonstrated stronger inhibitory effects of C1-INH on all complement pathways. The 
discrepancy could be explained by the use of different C1-INHs, suggesting that the purified C1-INH 
used in this study is more potent at inhibiting complement in vitro. 
The heparinoids used in this study are used clinically and known for a wide variety of 
biological effects. For years, it has been known that heparin inhibits all pathways of complement by 
blocking MASPs, C1q and by the potentiation of factor H.13,27,28 However, to our knowledge this is 
the first report that in addition to heparin, shows that low molecular weight heparins, that are widely 
used clinically, significantly inhibit all three complement pathways. Remarkably, although the different 
heparinoids are vastly similar in structure and molecular weight, clear differences are found in their 
ability to inhibit different pathways. Lastly, the pooled human serum used in this study to test the 
effect of heparinoids on the complement system already contains naturally-occurring C1-INH. One can 
therefore not exclude the possibility that part of the complement inhibition by heparinoids alone found 
in our experiment is through potentiation of C1-INH, naturally present in serum.
The present study also investigated the effect of heparinoids in the presence of C1-INH on 
complement activation. In 1920, Gross and Erch reported that heparin could potentiate C1-INH activity 
for the CP. The mechanisms by which heparin can potentiate C1-INH activity includes enhanced 
binding of C1-INH with C1s and interference with the binding of C1q to an activator. Therefore, it 
has been suggested that glycosaminoglycans might be clinically used as complement-inhibiting 
agents combined with C1-INH. Wuillemin et al. extensively studied the potentiating effects of several 
glycosaminoglycans on C1-INH to inhibit complement activation. Heparin was concluded to be one 
of the most potent enhancers of C1-INH function.23 In addition to previous studies, our study also 
investigated the potentiating effects of clinical heparinoids on C1-INH to inhibit complement activation 
for all three pathways. 
For the CP and LP, significant potentiation of C1-INH by heparinoids was found. In contrast, 
AP potentiation was found to be strictly heparinoid and dose dependent. Certain combinations of 
heparinoids and C1-INH were less effective in inhibiting the AP than C1-INH or the heparinoid alone. 
This might be explained by the known biphasic response of complement to heparin; at low concentration, 
heparin can activate the alternative pathway of complement through potentiation of the amplification 
loop; at a high heparin concentration, the alternative pathway is inhibited through potentiation of factor 
H, thereby preventing C3bBb-convertase formation.23,29–31 Interestingly, we found no biphasic effect for 
heparin or low molecular weight heparin alone, yet in certain combinations with C1-INH this biphasic 
effect occurred for the AP (supplementary data). It is suggested that, since inhibition of the AP by 
heparin is known to occur mainly through factor H potentiation, C1-INH either interferes with this 
binding, directly binds to heparin or it competes with the C3b-factor H complex. 
The effect on coagulation of heparinoids combined with C1-INH was also studied. In low 
concentrations the combined effect on the APTT was minimal. Nonetheless, at higher concentrations 
(0.5 and 1 IU/ml) the combined effect of C1-INH is more profound. The Prothrombin time (PT) was not 
significantly influenced by C1-INH, heparinoids or the combination (data not shown).
In conclusion, this study shows that plasma derived C1-INH inhibits complement activation 
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of all three pathways in a dose-dependent fashion. Furthermore, clinical used heparinoids potentiate 
the inhibitory capacity of C1-INH on all three pathways. For the AP, we demonstrated that within a 
range of different concentrations a biphasic effect occurs of both amplifying and reducing complement 
inhibition by C1-INH. These results shed new lights on the potential use of with C1-INH in order to 
target complement activation in the clinical setting. Potentially, heparinoids and C1-INH could be used 
combined as a cost-effective therapeutic option for the treatment of complement-mediated diseases. 
However, further, in vivo studies are needed to confirm the potentiating effect of combining heparinoids 
with C1-INH. 
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